First, Medicis (Restylane) put in a $2.8 billion bid to purchase Santa Barbara based Inamed (collagen, Hylaform, Captique) in March. However, the deal is moving ahead slowly. Two weeks ago, Allergan (Botox) submitted an unsolicited bid of $3.2 billion to purchase Inamed. The Board of Directors at Inamed responded with a positive sign stating that they asked management to review the offer. Last week, another Santa Barbara based manufacturer of breast implants, Mentor, submitted an unsolicited bid of $2.2 billion to purchase Medicis. Medicis immediately rejected the Mentor offer stating that they feel Inamed is a better partner for their business. Additionally, Medicis threatened to hold Inamed to a $90 million penalty if they back out of the original March deal and instead merge with Allergan.

We can't wait to see what happens next week! Who will we be purchasing our dermal fillers from?

Here are the latest stories:

Mentor Corporation Proposes to Merge with Medicis in $2.2 Billion All Stock Transaction Mentor Corporation, a leading supplier of medical products in the United States and internationally, announced that it has proposed a stock-for-stock merger with Medicis in which Medicis stockholders will receive 0.62 shares of Mentor common stock per Medicis share.

Medicis board unanimously rejects Mentor's purchase proposal The Board of Directors of Medicis has unanimously rejected an unsolicited proposal by Mentor Corporation to acquire Medicis by exchanging 0.62 of a share of Mentor for each share of Medicis. The Medicis Board confirmed that Medicis remains committed to completing its proposed merger with Inamed Corporation.

Mentor open to beefing up rejected Medicis deal Cosmetic-surgery product maker Mentor Corp. said Monday it would be open to beefing up its rejected $2.2 billion takeover bid for Medicis Pharmaceutical Corp.

Allergan commences stock exchange offer for Inamed shares On Monday, November 21, 2005, Allergan, Inc., a leading global specialty pharmaceutical company, commenced an exchange offer for all outstanding shares of Inamed Corporation under Allergan's previously announced proposal to acquire Inamed.

Medicis demands ultimatium from Inamed or pay $90 million break-up fee Medicis said Tuesday that it issued an ultimatum to intended merger partner Inamed Corp.’s board to spurn alternate suitor Allergan by Dec. 6 or pay a $90 million break-up fee. Medicis wants the Inamed board to make a formal recommendation to shareholders to vote against Allergan’s takeover.

Florida revokes medical license of two physicians for injecting fake Botox The state has revoked the medical licenses of two doctors at a shuttered clinic where the paralyzing botulism toxin was apparently injected in place of cosmetic Botox, the state Health Department said Tuesday.

Hope you enjoyed this week's news from MedSpaPress. You may click on www.medspapress.com to view more news from our industry.

Have a great week and we'll see you next Monday!

Your MedSpa Press Monday Messenger